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Abstract
Background: Opioid prescribing for chronic pain is common and controversial, but recommended clinical practices 
are followed inconsistently in many clinical settings. Strategies for increasing adherence to clinical practice guideline 
recommendations are needed to increase effectiveness and reduce negative consequences of opioid prescribing in 
chronic pain patients.
Methods: Here we describe the process and outcomes of a project to operationalize the 2003 VA/DOD Clinical Practice 
Guideline for Opioid Therapy for Chronic Non-Cancer Pain into a computerized decision support system (DSS) to 
encourage good opioid prescribing practices during primary care visits. We based the DSS on the existing ATHENA-
DSS. We used an iterative process of design, testing, and revision of the DSS by a diverse team including guideline 
authors, medical informatics experts, clinical content experts, and end-users to convert the written clinical practice 
guideline into a computable algorithm to generate patient-specific recommendations for care based upon existing 
information in the electronic medical record (EMR), and a set of clinical tools.
Results: The iterative revision process identified numerous and varied problems with the initially designed system 
despite diverse expert participation in the design process. The process of operationalizing the guideline identified 
areas in which the guideline was vague, left decisions to clinical judgment, or required clarification of detail to insure 
safe clinical implementation. The revisions led to workable solutions to problems, defined the limits of the DSS and its 
utility in clinical practice, improved integration into clinical workflow, and improved the clarity and accuracy of system 
recommendations and tools.
Conclusions: Use of this iterative process led to development of a multifunctional DSS that met the approval of the 
clinical practice guideline authors, content experts, and clinicians involved in testing. The process and experiences 
described provide a model for development of other DSSs that translate written guidelines into actionable, real-time 
clinical recommendations.
Background
Promoting use of good care practices is necessary for safe
and effective use of opioid therapy for chronic non-can-
cer pain, but achieving provider adherence to clinical
practice guideline (CPG) recommended care practices
has proven difficult in most primary health care settings
[1-3]. Increased attention to the importance of pain man-
agement has led to increased prescribing of analgesic
medications [4]. Opioid analgesics are among the most
prescribed medications in the US today [5,6] and, as of
2008, hydrocodone was the top prescribed medication in
the country [4]. However, increased use of these powerful
and potentially addictive medications has had negative
consequences. Rates of opioid overdose, prescription opi-
oid misuse and addiction, diversion of prescribed medi-
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Page 2 of 11cations toward illicit use, and opioid-related legal suits
against physicians have all increased to a disturbing
extent [4,5]. Use of recommended care practices is con-
sidered essential for minimizing these negative conse-
quences without reversing gains made in improving pain
management in clinical settings.
In 2003, the Veterans Administration (VA)/Department
of Defense (DOD) published a CPG for use of opioid
therapy for the treatment of chronic non-cancer pain [7].
The goals included using evidence-based recommenda-
tions to improve analgesia, promote uniformity of care,
and decrease related morbidity of patients with non-can-
cer chronic pain in the primary care setting. This guide-
line provides detailed information about appropriate
dosing, including protocols for initiation, titration, and
cessation of the most commonly used opioid medica-
tions. It provides information on potential contraindica-
tions for opioid therapy for chronic pain and suggestions
for opioid management in patients at higher risk of mis-
use, diversion, adverse effects, overdose, and/or lack of
efficacy. A substantial portion of the guideline focuses on
processes of care. For example, the guideline encourages
clinicians to: regularly conduct assessments of pain and
functioning; use urine drug screening protocols to dis-
courage and detect medication misuse and diversion;
obtain written agreement on the parameters and respon-
sibilities of the patient regarding the opioid prescription;
provide clear education on both the risks and realistic
level of benefit from opioid analgesics; and carefully doc-
ument and follow treatment plans. This framework can
increase clinician's confidence in appropriately prescrib-
ing opioid therapy.
Despite expert consensus on the importance of adher-
ence to these care guidelines, there is little evidence that
they are consistently followed in actual clinical practice
[8]. Numerous barriers to providing guideline-adherent
care exist [9]. Clinicians report lack of training in both
pain management and addiction medicine and are
uncomfortable assessing and treating these conditions.
Moreover, patient-provider communication about opi-
oids is complicated by: the subjective nature of pain expe-
rience, which prevents physicians from objectively
verifying the severity of the pain condition; the reinforc-
ing effects of opioid drugs, which may lead to either
deliberate or unknowing attempts by the patient to obtain
opioid medications; provider and patient fears about the
consequences of either prescribing a potentially addictive
medication or under-managing pain; and stigma associ-
ated with substance use disorders [10-12]. Because of
these communication difficulties, providers may be hesi-
tant to prescribe opioid medications initially, to discon-
tinue medication when there is no clear sign of benefit,
and to address the addictive nature of opioid analgesics
and the possibility of misuse. In all cases, these behaviors
lead to suboptimal care. Additionally, poor care coordina-
tion within the health care system contributes to poor
opioid management [13]. Lack of clear documentation of
pain management plans and opioid use agreements and
lack of communication between providers can lead to
inconsistent treatment and poor prescribing decisions
that contribute to misuse and poor pain management.
Lastly, good care practices take time, and time limitations
and competing demands during outpatient visits in pri-
mary care may limit clinician adherence to guidelines.
Developing health services interventions that address
these barriers is essential for improving opioid manage-
ment in chronic pain. A computerized decision support
system (DSS) may provide such an intervention [14,15],
and some DSSs have been shown to increase adherence
to guideline recommended care [16]. Hunt and colleagues
systematically reviewed randomized controlled trials of
DSSs, defined as 'any electronic or non-electronic system
designed to aid directly in clinical decision making, in
which characteristics of individual patients are used to
generate patient-specific assessments or recommenda-
tions that are then presented to clinicians for consider-
ation' [17]. Kawamoto and colleagues identified features
that were independently associated with improved clini-
cal practice in a multiple regression analysis. These
included: automatic delivery, presentation of the DSS
when and where clinical decision making occurs, provi-
sion of concrete recommendations of how to proceed,
and computer-based generation of decision support [18].
A model computerized DSS (ATHENA-DSS) that links
with the electronic medical record (EMR) system used by
the VA Health Care System (VistA) was designed to pro-
vide these key features [19-22]. ATHENA-DSS, devel-
oped using the EON guideline decision-support
technology [23,24], accesses patient information in the
EMR, evaluates this information in terms of a knowledge
base consisting of encoded CPG recommendations, gen-
erates patient-specific recommendations, and presents a
graphical user interface with these recommendations
along with tools and information support to clinicians
when they open the EMR of a relevant patient at the time
of the clinic visit.
We used an iterative development process involving
authors of the CPG, local content experts, end-users (i.e.,
opioid prescribers), knowledge modelers, graphic design-
ers, and systems software engineers to modify the initial
ATHENA-DSS, ATHENA-Hypertension (HTN), to guide
evidence-based opioid prescribing (Figure 1). We named
this newly developed system ATHENA-Opioid Therapy
(ATHENA-OT) [25]. Here, we describe the process and
outcome of this iterative development via which we oper-
ationalized CPG information into a computer-interpreta-
ble knowledge base to provide patient-specific
recommendations for care, and clinical tools to encour-
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usability testing was also a crucial component of ATH-
ENA-OT development, but these processes will be
described elsewhere [26]. A valuable part of our process
is collaboration of the DSS developers directly with the
CPG authors. The process described provides a model for
translating guidelines into DSSs, including methods to
ensure that the DSS retains the intent of the CPG authors
and encourages use of good care practices through inclu-
sion of patient-specific recommendations and clinical
tools.
Methods
The patient safety features and a thorough description of
the ATHENA-OT graphical user interface have been
described previously [25]. This study was approved and
overseen by the Stanford University Human Research
Protection Program and the VA Palo Alto Health Care
System Research and Development Committee.
In the process described, the team started with the
CPG and translated it into three primary products: an
operationalized algorithm in Protégé/EON, a matching
written Rules Document, plus a set of clinical tools (Fig-
ure 1). We based our guideline translation process on
experience gained in development of ATHENA-Hyper-
tension as well as general principles from medical infor-
matics literature encouraging iterative design based on
interim evaluation and testing (for example, the ADDIE
(Analysis, Design, Development, Implementation and
Evaluation) process [27]. The accuracy testing procedures
for both the Protégé/EON algorithm and the clinical tools
were adapted from those initially designed and success-
fully used by the ATHENA-Hypertension development
team [28]. The Rules Document validation process was
designed for ATHENA-OT and has not been previously
described, and thus we report this process and findings in
greater detail.
A knowledge management team (KM) consisting of the
study managers, knowledge modelers (SBM and MM,
medical informaticists with expertise in translation of
clinical knowledge into encoded computer-interpretable
formats using a knowledge acquisition program called
Protégé [29]), and system software experts drafted,
revised, and managed the review of these 3 products.
Each of these three products were reviewed and revised
through separate procedures and distinct, but overlap-
ping teams. Revisions to the Protégé/EON algorithm and
the Rules Document were made in tandem to maintain
consistency, based on feedback from the accuracy and
rules validation testing. These processes occurred itera-
tively during ATHENA-OT development. Each of the
processes, as well as major revisions, are described below.
Drafting a Rules Document and operationalized algorithm 
in Protégé/EON
To create an encoded guideline, one must specify details
that are not explicitly included in the CPG [30]. For
example, the CPG for opioid therapy states: 'long-acting
agents are effective for continuous, chronic pain'. This
statement fails to specify which medications should be
considered 'long-acting agents' and the definition of con-
tinuous, chronic pain. In order for the computer to be
able to use this information, the definitions of 'long-act-
ing agents' and 'continuous, chronic pain' must be explic-
itly defined or operationalized.
To operationalize the 2003 VA/DOD 'Clinical Practice
Guideline for Opioid Therapy for Chronic Non-Cancer
Pain', the KM, the medical director, and clinical nurse
specialist who direct the VA Palo Alto Health Care Sys-
tem Pain Management Clinic worked collaboratively to
create a draft of the guideline knowledge to be encoded in
Protégé and specify concepts that were not clearly
defined. The process involved the KM reviewing the CPG
and attempting to translate the contained recommenda-
tions into well-defined concepts that could be encoded in
terms of a computer-interpretable model of CPGs [23].
The KM referred questions to clinical experts to itera-
tively refine the encoded guideline. In addition to encod-
ing the knowledge in Protégé/EON, a 'Rules Document'
was created that provided a written description in simple
but highly-specified English of the included concepts and
rules that the developers intended to encode. The Rules
Document serves as a format for review by clinicians and
CPG authors [28].
Review processes
Accuracy testing of the Protégé/EON algorithm
Experts in opioid therapy for chronic pain, including the
clinical nurse specialist at the VA Palo Alto Pain Manage-
ment Clinic, a Ph.D. researcher specializing in opioid
pharmacology and behavior, a primary-care physician,
Figure 1 Model of CPG translation and revision. This figure de-
scribes the products, review processes and reviewers for the three 
main products of the ATHENA-OT CPG translation project.
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atively during the development and refinement of the
operationalized algorithm. Accuracy testing involved
examination of ATHENA-OT recommendations for real
patient cases with recent primary care visits selected
from the VA Palo Alto's EMR. ATHENA-OT generated
definitions and recommendations that were compared to
information in the EMR and to expert assessment of the
patient case in the EMR using the CPG recommenda-
tions. Straightforward errors in the generated recommen-
dations were noted and sent to the KM for immediate
correction (e.g., miscoding of a diagnosis or minor word-
ing changes). Concerns involving clinical recommenda-
tions were first discussed by the expert reviewers, and
final suggestions for changes to the encoded guideline
were sent to the KM. When suggestions were outside the
boundaries of the DSS, the KM met again with the expert
reviewers to discuss options and insure that the boundar-
ies were made clear to clinical users to avoid false expec-
tations on the part of the user about the system's
capabilities.
Validation of the draft Rules Document by authors of the CPG
Once the encoded guideline had been pilot tested for
accuracy and the Rules Document updated to match the
current content of the encoded guideline, the Rules Doc-
ument was sent to three authors of the 2003 VA/DOD
Opioid Therapy for Chronic Non-Cancer Pain CPG (MC,
JR, CS). For each clinical rule, the authors were asked to
consider the CPG and indicate first whether the clinical
rule agreed with the intent of the CPG as written or was
incorrect based upon the intent of the CPG. Second, they
were asked to comment when the Rules Document was
not clear and further clarification of intent of the encoded
guideline was required. The guideline-authors' comments
included details regarding clinical rules with which they
disagreed or that they thought needed refinement. This
feedback was used to revise the Rules Document and Pro-
tégé/EON algorithm to address the guideline authors'
concerns.
Clinical tool design
The CPG contained many recommendations to support
good clinical care practices that were best shared with
primary care clinicians through easily accessible tools
(links within the DSS). In discussion with VA Palo Alto
clinicians in the Pain Management and Primary Care
Clinics, the KM developed information sheets and other
clinical tools within ATHENA-OT to facilitate adherence
to the CPG recommendations. These tools were vetted
and, where appropriate, pilot tested for accuracy by the
clinical staff at the pain management clinic and opioid
experts on the project team.
User interface design
A final step in translating the CPG into ATHENA-OT
was determining how to present patient-specific recom-
mendations and clinical tools to the clinicians most effec-
tively. Accordingly, in consultation with a graphic design
firm, we used an iterative design and evaluation process
to optimize the graphical user interface. This process is
described elsewhere [26]. While it is difficult to com-
pletely dissociate the development of the user interface
from the process of translating the guideline, here we
focus only on development of clinical tools and patient-
specific recommendations suggested in the CPG.
Revision of the Rules Document and Protégé/EON algorithm
Based upon feedback from the review processes, a sub-
stantial redesign of the algorithm was conducted. Follow-
ing system redesign, in depth re-testing of the accuracy
the Protégé/EON algorithm was conducted, and the
revised Rules Document was again sent out to the three
CPG authors for a second round of validation. The CPG
authors indicated additional areas of disagreement or
requirements for clarification. In this round, the exact
wording of DSS recommendations was provided for
review. Final consensus on the Rules Document was
obtained by conducting follow-up phone calls and emails
with the CPG authors where remaining changes were
planned, specified, and approved.
Results
Drafting of a Rules Document and operational algorithm in 
Protégé/EON
The KM and clinical experts met approximately 30 times
over the course of nine months, and had extensive email
communication. The encoded guideline in Protégé/EON
included: operationalized definitions of all the concepts
included in the guideline (e.g., the ICD-9 codes corre-
sponding to a named diagnosis, or the pharmacy codes
for medications of a specified class); an algorithm that
operationalized guideline recommendations in terms of
the relevant patient scenarios, management decisions,
and alternative actions; a collection of situations that
warrant warning messages; and declarative specification
of the indications, contraindications, and dose ranges of
classes of opioids.
Because it is not possible to encode all medical knowl-
edge, clinical DSSs must attend to specifying boundaries
and planning system performance at the boundaries
[31,32]. Some of the guideline knowledge relies on clini-
cal concepts that are difficult to operationalize and/or call
for data not available in computable formats from the
patients' EMR. We set these as boundaries of ATHENA-
OT and specified plans for system behavior at the bound-
ary (see Table 1 for examples).
Round one review
Accuracy testing of the Protégé/EON algorithm
Accuracy testing of the Protégé/EON algorithm identi-
fied numerous errors in CPG coding that were subse-
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included omissions of important medical record data in
the ATHENA-OT data extract and miscoding of concepts
such that recommendations were not produced as
planned. Less commonly, clinical cases that had not been
anticipated previously by the KM and clinical experts
were identified that required refinement of recommenda-
tions to align with the assumed intent of the CPG.
In round one assessment the CPG authors agreed with
many but not all the clinical rules specified in the Rules
Document (table 2). However, they also identified some
broad conceptual problems with the design of the DSS.
CPG authors often objected to strict recommendations
based on patient diagnoses. For example, the initial DSS
eligibility criteria excluded all patients with a cancer diag-
nosis because the guideline indicated that the recommen-
dations for opioid therapy were specifically for non-
cancer pain. CPG authors highlighted their disagreement
with this decision because it would prevent the system
from providing recommendations to those patients with
non-cancer-related chronic pain who also happened to
have cancer. There was also some disagreement among
CPG authors about the broad issue of whether ATHENA-
OT should provide firm discontinuation recommenda-
tions based on the presence of substance abuse and psy-
chiatric diagnosis. Moreover, comments from CPG
authors made it clear that accurate decisions about
whether medication should be increased, decreased, or
discontinued could not be made using only information
available in the EMR. These comments helped clarify sit-
uations where clinicians might appropriately either
ignore or decide against guideline recommended actions
based on information not in the EMR, allowing alteration
of the DSS to encourage less rigid use of recommenda-
tions in these circumstances.
Thus, CPG authors' comments in round one Rules
Document assessment suggested problems with an over-
all decision support strategy of providing clinicians with a
single actionable recommendation for opioid prescribing
(e.g., 'increase dose of medication [X] by [Y] mg'). Guide-
line author comments made it clear that clinician judg-
ment, patient preferences, and information not available
in the EMR were crucial to providing CPG-adherent opi-
oid therapy, and that a decision support strategy provid-
ing greater clinical flexibility would be more appropriate.
Revision of the Rules Document and Protégé/EON algorithm
A substantial redesign was conducted. This redesign
addressed several concerns that had not previously been
solved because of lack of consensus or detail in the CPG
or lack of information in the EMR. Instead of displaying
our best 'guess' about the recommended course for opioid
prescribing, we decided to display all possible therapeutic
options for the provider to select from based on clinical
judgment. Specifically, we switched from presenting cli-
nicians with detailed procedural or dosing recommenda-
tions for the system's one best guess regarding the
appropriate strategy for dosing change (i.e., start medica-
tion, increase dose, decrease dose, switch to a different
medication, or stop medication) to providing detailed
procedural or dosing recommendations for all possible
options with presentation of indications and contraindi-
cations for each choice. This modification emphasized
the fact that clinical decisions about overall strategy for
opioid therapy require assessment of physical and social
functioning and the patients' goals and preferences for
treatment as well as clinical judgement. Thus, this clinical
Table 1: Examples of Boundaries of ATHENA-Opioid 
Therapy
Issue Solution
Lack of expert consensus on 
specific criteria for judging an 
opioid trial as failed and thus 
appropriate to discontinue.
The determination of 
whether to discontinue an 
opioid medication was left to 
clinical judgment and always 
presented as an option. 
Detailed instructions on how 
but not when to discontinue 
the opioid medication were 
provided.
CPG was written to guide 
prescribing for non-cancer 
pain. Some patients have 
cancer plus pain from non-
cancer-related causes, 
making it unclear whether 
the CPG was appropriate to 
apply.
ATHENA-OT issued a warning 
when the patient had cancer 
and indicated that system 
recommendations may not 
be appropriate if the 
patient's pain was caused by 
the cancer.
Determination of the severity 
of illness requires clinical 
assessment during the 
current visit.
ATHENA-OT issued a warning 
about potentially concerning 
diagnoses and 
recommended that the 
clinician assess the patient's 
current status to clarify if 
opioid dose adjustments 
were necessary.
In the electronic medical 
record (VistA), allergies are 
not distinguished from 
adverse events.
As a conservative measure, 
any record of an allergy/
adverse event was 
considered an allergy, and 
recommendations were 
generated based on this 
assumption. This definition 
was clarified in clinician 
training sessions.
The table above provides examples of portions of the guideline 
that were not encoded. For each example, we describe how this 
boundary of the DSS was indicated in ATHENA-OT.
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visit and cannot be made based on information solely in
the EMR. This design choice allowed the team to focus
ATHENA-OT on insuring safe and informed implemen-
tation of treatment strategies following a shared clinical
decision-making model [11].
Round two review of the Protégé/EON algorithm and Rules 
Document
Accuracy testing was conducted again. Errors in Protégé/
EON coding were identified and corrected, and wording
of recommendations was edited as recommended by the
expert testers. After the Rules Document was updated
based on the comments from the initial assessment and
the system redesign, CPG authors re-evaluated the clini-
cal rules (See Appendix 2 for the Rules Document for
round two review). Notably, in round two, the wording of
clinical recommendations was included in the Rules Doc-
ument for approval and comment. In this second round
review, CPG authors indicated increased consensus on
the Rules Document used for ATHENA-OT. The CPG
Table 2: Clinical practice guideline author agreement with Rules Document
Rule Category Agreement (%) Clarification (%)
Round one Round two Round one Round two
Drug 
recommendations 
overall
82 79 24 21
1) Initiation 
dosing
93 43 7 64
2) Titration dosing 89 89 11 0
3) Switching 
dosing
100 100 14 0
4) Cessation 
dosing
28 100 86 0
5) Medication 
choice
- 100 - 0
Contraindications/
warnings overall
84 86 44 12
1) Medical 
contraindications
80 69 75 0
2) Psychiatric 
contraindications
94 89 30 15
3) Psychosocial 
contraindications
63 100 47 0
Patient eligibility and 
exclusion
66 100 44 0
% Agreement indicates the percentage of rules in each category for which all three authors indicated agreement. % Clarification indicates 
the percentage of rules in each category where at least one author identified problems with the rule that needed to be addressed to ensure 
agreement with the CPG.
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rules as written, and they requested clarification of fewer
clinical rules, with the notable exception of several sug-
gestions for detailed modifications which affected many
of the rules for initiation dosing and contraindication
warnings (Table 2). These exceptions are discussed below.
As the Rules Document became more defined and
refined, CPG author concerns and comments became
more detailed. Suggested changes and clarifications
became more minor, although the number of suggestions
did not decline in every category. While major redesign
of ATHENA-OT was required to address guideline
author comments in round one, round two revisions were
minor enough to be resolved with small wording changes
in existing patient-specific recommendations or slight
modification of diagnostic definitions. These changes
were discussed and approved in follow-up telephone calls
with the CPG authors.
Table 3 shows example areas of disagreement of the
CPG authors with the Rules Document, and the revisions
made in response. One disagreement that affected a clus-
ter of recommendations was not identified until round
two, but was important for patient safety and included
details not explicitly specified in the CPG. Specifically, a
guideline author expressed concern about non-steroidal
anti-inflammatory drug (NSAID) or acetaminophen
overdose related to prescription of short-acting opioid
medications combined with NSAIDs/acetaminophen in
the absence of an assessment of additional use of over-
the-counter or prescribed NSAIDs/acetaminophen, and
suggested this be noted in ATHENA-OT initiation rec-
ommendations. We note that this concern was identified
only very vaguely in the CPG, which stated just that an
assessment of patient's current medications be conducted
before initiation of opioid therapy. This omission affected
many of the recommendations for initiation of short-act-
ing medication, but was easily corrected through a simple
change of wording in the recommendations. Additionally,
once the accuracy of clinical recommendations was less
of an issue, CPG authors began to consider the relative
importance of recommendations in their decisions. This
revealed differences of opinion about the strength of
wording of some recommendations, and whether accu-
rate, but rarely important, recommendations should be
displayed at all. For example, we issued a warning mes-
sage about use of opioid therapy in patients with a diag-
nosis of a DSM-IV Axis II personality disorder, and a
guideline author suggested the message be specific to
psychopathy, sociopathy, anti-social personality, and bor-
derline personality. These requests for changes during
second round evaluation led to lower agreement rates for
initiation dosing, and medical and psychiatric contraindi-
cations (Table 3). However, the CPG authors did not find
their colleagues' suggested revisions controversial, and
there was general agreement during follow-up that addi-
Table 3: Examples of areas of disagreement in the Rules Document and revisions
Round Examples of disagreement Guideline author's 
reasoning
Revisions made in response
Round one Strict discontinuation 
messages based on substance 
abuse or psychiatric diagnosis
Need to evaluate current 
status of diagnosis
Updated algorithm to 
generate all therapeutic 
options with 
contraindications for provider 
to consider and apply based 
on clinical judgement
Round one Warning for patients that live 
>200 miles from VA.
Patients may have continuity 
of care even if living far away.
Recommendation to not 
provide opioid therapy and 
refer patient for care with a 
local provider was removed
Round two Dose recommendation for 
short acting opioids 
combined with NSAIDs/
acetaminophen
Concern about dose of 
NSAIDs/acetaminophen with 
medication combinations
Wording of message updated
Round two Warning about patients with 
personality disorder
Warn specifically about anti-
social and borderline 
personality disorders
Restricted warnings to 
persons with these specific 
personality disorder 
diagnoses.
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of detail in the original CPG represented improvements.
Clinical tools development
The CPG provided information regarding definitions,
assessment and documentation requirements, patient
education materials, clinical referral needs, and dosing
conversion tables that could not be efficiently presented
as patient-specific recommendations. To include these
elements of the guideline in ATHENA-OT, we developed
clinical tools and information sheets that were incorpo-
rated into menus on the graphical user interface. These
tools were derived from the CPG with additional input
from pain experts and primary care providers.
These clinical tools included interactive systems, such
as a conversion calculator (Additional file 1) that was cre-
ated based on tables in the guideline to facilitate dose
conversion when switching between opioids. Interactive
assessment instruments were also developed to improve
CPG adherence. The CPG recommends that clinicians
conduct and document a comprehensive biopsychosocial
assessment of pain before opioid prescribing and at sub-
sequent visits. Discussion with local primary care clini-
cians in usability testing revealed that such assessments
were not completed in a standardized manner and that
clinicians were uncertain about the detailed elements that
should be included in their assessments. Experts and tar-
get users agreed that a standardized pain assessment
form that could be written back into the EMR would be
helpful for clinicians conducting these pain assessments
and reassessments. We designed such a pain assessment
(Additional file 2) based upon existing tools and the rec-
ommendations of the local pain clinic staff. This tool pro-
vided check boxes to record patient information that
could be written back into a structured progress note
(Additional file 3) in the patient EMR for clinician review
and signature.
Some information sheets were created to provide
locally tailored versions of information for providing
guideline-adherent therapy. For example, a contact list for
local referral sources for pain, addiction, rehabilitation,
and behavioral therapy was created. Similarly, state legal
requirements for documentation of opioid management
were outlined in another information sheet. We also
included simple pre-existing information sheets and
patient education documents to ensure that these were
readily accessible to clinicians.
Discussion
Collaboration on an iterative design process between the
ATHENA-OT developers, local content experts, and the
authors of the CPG for management of opioid therapy for
chronic pain identified issues that arise in encoding a DSS
and provided a mechanism for their resolution, resulting
in an automated DSS that fulfils the intentions of the
CPG authors.
Clinicians who provide care for patients based on
guidelines must operationalize them to carry out care.
Operationalizing CPGs for automated DSS highlights the
context, assumptions, ambiguities, and gaps that are
inherent in the usual formats of CPGs [30]. Encoding the
DSS requires interpreting the context, specifying con-
cepts, clarifying embedded assumptions, spanning gaps,
and resolving ambiguities in source documents. Evidence
sources for recommendations can sometimes serve as
sources for specification of concepts (e.g., which specific
diagnoses were included in the original study that forms
the evidence base for a particular recommendation) or
target population assumptions, but do not fill all the gaps.
Consensus-based recommendations may present a par-
ticular challenge for translation into computerized DSS.
These recommendations typically do not reference scien-
tific studies on which definitions of concepts or cut-
points for decisions could be based [30]. Without partici-
pation of the CPG authors, who have extensive expert
knowledge beyond what is written into the CPG docu-
ment, the intent or specificity of the guideline may be
altered as it is translated into a computerized DSS. In
developing ATHENA-OT, we used a two-phase process
including accuracy testing plus a review of the guideline
rules by three authors of the CPG, followed by a final
round of telephone and email communications to arrive
at a final version meeting approval of the CPG authors.
This process clarified details of the recommendations
and better specified patient populations for whom rec-
ommendations were relevant. However, the process was
made more challenging by the consensus nature of the
guidelines. There was not perfect agreement among the
CPG authors for all recommendations. Moreover, in
some cases, it seemed apparent that some vague areas of
the guideline were purposefully written to be vague, an
option that could not be directly incorporated in the
computerized algorithm beyond careful wording of the
recommendations. Encoding the guideline into a DSS
revealed areas of the guideline that lacked specificity and
therefore might be difficult to implement both in the DSS
and clinically. We note that the opioid therapy guidelines
may have been more challenging to operationalize than
other guidelines in this regard, due to the extreme hetero-
geneity of patients and underlying health conditions, lim-
ited evidence-base for many criteria, and controversies
surrounding treatment.
Operationalizing the opioid therapy for chronic pain
guideline was further complicated by the fact that good
opioid prescribing decisions require consideration of
behavioral, mental health, and psychosocial conditions
and functioning. Moreover, patient preferences and goals
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apy. Prescribing decisions involve striking a balance
between pain control, adverse-effect management, physi-
cal and emotional function, and addiction risk. This
information can be efficiently obtained only in discussion
between patient and provider; there is little to no com-
putable information recorded in the medical record to
indicate biopsychosocial functioning and patient prefer-
ences to guide such decisions. What information is avail-
able in the medical record is typically contained in free-
text notes rather than structured data fields and would
require advanced text mining algorithms to access, an
option that may be available in the future. To design a
functional DSS, the expert team was required to consider
how the algorithm could usefully support prescribing
decisions while not having access to crucial information
required to guide opioid prescribing. To overcome these
limitations, the expert team designed a DSS that would
highlight important clinical information available in the
medical record, provide many tools to support shared
decision making, facilitate appropriate documentation,
and present a checklist of important items to review
when considering opioid therapy.
An issue that led to difficulties in getting expert con-
sensus was the problem of differentiating between accu-
rate information and information that was of high clinical
priority. There was disagreement among the expert team
and CPG authors about whether all accurate information
should be provided by the DSS, or whether messages
should be limited to issues that were clearly important
enough to warrant taking primary care clinicians' time.
The process of obtaining consensus on the system could
be streamlined by clarifying whether the goal of rules
development was to identify all clinically accurate recom-
mendations that could be made from EMR data, or to
identify important clinical recommendations for typical
primary care practice. The process of analysing the
encoded guideline rules presented the guideline informa-
tion in a different way to guideline authors leading to new
insight on their part. This insight made explicit some
implicit assumptions by showing varying ways the guide-
line could be interpreted and applied, which may not
have been the intention of the guideline authors.
The wording of recommendations and design of clinical
tools evolved alongside the operationalization for the
guideline. Striking a balance between detail, accuracy,
and clinical utility was difficult, with disagreements
among the diverse members of the development and
evaluation team leading to dynamic changes in the con-
tent of recommendations in terms of prioritization, tone,
and wordiness. The CPG suggested tools that would facil-
itate guideline recommended care processes, but expert
and end-user input was needed to optimize content and
design. For example, based on feedback from clinician
members of the team and usability testing [26], we imple-
mented a write back capacity of the pain assessment tem-
plate.
Experience with this iterative process suggested several
improvements that might have streamlined CPG transla-
tion into a DSS. Specifically, we would now recommend:
1. Including an explicit focus on defining the boundar-
ies or limits of the DSS and how they would be handled at
the start of the translation process. Outlining these in the
Rules Document for review would help ensure that they
are considered and addressed thoroughly during initial
DSS design.
2. Collecting information from CPG authors regarding
prioritization of DSS recommendations during review of
the Rules Document. Both CPG authors and end-users
participating in usability testing [31] brought up issues
regarding distinguishing the clinical importance of rec-
ommendations.
3. Presenting specific wording of DSS recommenda-
tions as well as an indication of whether the wording
should be presented on the main screen or only after end-
user interaction with the system (e.g., presented following
a mouse click) to CPG authors to review as part of the
Rules Document. Subtle wording changes in the DSS rec-
ommendations could alter author consensus on recom-
mendations.
Summary
An iterative process of drafting, testing, reviewing, and
revising the DSS content enabled us to develop a DSS that
usefully operationalized the written CPG for opioid ther-
apy for chronic pain into a system that could provide real-
time decision support in clinical settings. Including
guideline authors alongside the local expert team in the
iterative development of the content resulted in a product
that was considered consistent with the intent of the
guideline and amenable to implementation with the local
EMR and patient population. The process and experi-
ences described here provide a model for development of
the content other DSSs attempting to translate written
CPGs into actionable, real-time clinical recommenda-
tions and tools.
Additional material
Additional file 1 Conversion calculator tool. Picture of a conversion cal-
culator tool to support clinicians calculating dose equivalents when con-
verting from one opioid drug to another.
Additional file 2 Pain Assessment tool. Picture of the pain assessment 
tool clinicians can interact with and write to the medical record.
Additional file 3 Note in medical record from pain assessment tool. 
This is a picture of a note written to the electronic medical record when cli-
nicians complete the pain assessment tool.
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